Anti‐VEGF drugs are effective at improving vision in people with DMO with three to four in every 10 people likely to experience an improvement of 3 or more lines VA at one year (Cochrane Database of Systematic Reviews)
Diabetes News
Glycosmedia is dedicated to bringing free, non-promotional, editorially independent news to a global audience about developments in diabetes, and is primarily aimed at health professionals.
Cardiovascular and mortality events in type 2 diabetes cardiovascular outcomes trials: a systematic review with trend analysis
In contrast to real-world data, there was no evidence of an improvement in all-cause and cardiovascular mortality in type 2 diabetes participants included in control arms of randomised clinical trials across 5 decades. Further studies should investigate whether and how dissimilarities in populations, procedures, and assessments of exposures and outcomes explain the differences between real-world setting and clinical trials (Acta Diabetologica)
Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study
In this analysis of nationwide registers from two countries, use of SGLT2 inhibitors, as compared with GLP1 receptor agonists, was associated with an increased risk of lower limb amputation and diabetic ketoacidosis, but not with other serious adverse events of current concern (BMJ)
Carbohydrate restriction for glycaemic control in Type 2 diabetes: a systematic review and meta‐analysis
There was no overall pooled effect on HbA1c in favour of restricting carbohydrate; however, restriction of carbohydrate to 50–130 g per day had beneficial effects on HbA1c in trials up to 6 months (Diabetic Medicine)
Fasting Plasma Glucose Indicates Reversibility of the Acute Insulin Response after Short-Term Intensive Insulin Therapy in Patients with Various Duration of Type 2 Diabetes
We concluded that recovery of the AIR could be obtained in T2DM patients of varying disease duration by short-term intensive insulin therapy and it could be conveniently estimated using posttreatment fasting plasma glucose and other fasting indicators (Journal of Diabetes Research)
The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients
This study suggests that the ratio of AGE to sRAGE may be a surrogate biomarker for microvascular injury (BMC Endocrine Disorders)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes
SGLT2i have moderate benefits on atherosclerotic major adverse cardiovascular events that seem confined to patients with established atherosclerotic cardiovascular disease. However, they have robust benefits on reducing hospitalisation for heart failure and progression of renal disease regardless of existing atherosclerotic cardiovascular disease or a history of heart failure (The Lancet)
The Physical Activity Guidelines for Americans
The Physical Activity Guidelines for Americans, 2nd edition, provides information and guidance on the types and amounts of physical activity that provide substantial health benefits (JAMA)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure (NEJM)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Among adults with type 2 diabetes and high CV and renal risk, linagliptin added to usual care compared with placebo added to usual care resulted in a noninferior risk of a composite CV outcome over a median 2.2 years (JAMA)
Prescribing for Diabetes in England – 2007/08 – 2017/18
Prescribing for Diabetes reports on and examines prescribing trends on medicines prescribed in primary care in England for the treatment and monitoring of diabetes during the period April 2007 to March 2018 (NHS Digital)
National Diabetes Audit Report 1 Care Processes and Treatment Targets 2017-18
A full report will be published in March 2019, which will contain full key findings, recommendations and results of initial analyses into cardiovascular risk reduction and the use of statins (NHS Digital)
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes
Discontinuation of treatment with DPP-4 inhibitor should be considered for patients with diabetes when BP is diagnosed; the recently increased use of DPP-4 inhibitors may explain in part the increasing incidence of BP (JAMA Dermatology)
Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial)
Renal biomarkers informing various aspects of kidney function may further our understanding of the complex interplay between diabetic kidney disease and cardiovascular disease (American Journal of Cardiology)
Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial
ASP8232 is effective in reducing albuminuria in patients with diabetic kidney disease and is safe and well tolerated. These findings warrant further research to ascertain the effect of ASP8232 on delaying progression of diabetic kidney disease (The Lancet Diabetes & Endocrinology)
Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross‐over trial
People with type 2 diabetes experienced improved postprandial and 24 h glycaemia and decreased blood pressure after 4 months of AA supplementation when compared to placebo. These findings offer evidence for the proposed use of AA as an adjunct therapy to improve glycaemic and blood pressure control in people with type 2 diabetes (Diabetes, Obesity and Metabolism)
Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycemia (Diabetes, Obesity and Metabolism)
Efficacy of a self-management education programme on patients with type 2 diabetes in primary care: A randomised controlled trial
HbA1c reductions are difficult to obtain in adequately controlled patients. On the other hand, raising awareness on one´s disease can increase disease control self-efficacy. This finding, accompanied by reduced medication consumption and healthcare use rates, highlights that usual care would be benefited by incorporating certain SDSMP aspects (Primary Care Diabetes)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Lixisenatide reduces progression of UACR in macroalbuminuric patients, and is associated with a lower risk of new-onset macroalbuminuria after adjustment for baseline and on-trial HbA 1c and other traditional renal risk factors (The Lancet Diabetes & Endocrinology)
Comparative efficacy of individual renin–angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis
Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes (Nephrology Dialysis Transplantation)
- 1
- 2
- 3
- …
- 170
- Next Page »
Glycosmedia is also available as an App: